title: Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience.
abstract: From March 2003 to April 2004, 77 physicians throughout France prospectively recruited 1289 ductal carcinoma in situ (DCIS) patients and collected data on diagnosis, patient and tumour characteristics, and treatments. Median age was 56 years (range, 30-84). Ductal carcinoma in situ was diagnosed by mammography in 87.6% of patients. Mastectomy, conservative surgery alone (CS) and CS with radiotherapy (CS+RT) were performed in 30.5, 7.8 and 61.7% of patients, respectively. Thus, 89% of patients treated by CS received adjuvant RT. Sentinel node biopsy (SNB) and axillary dissection (AD) were performed in 21.3 and 10.4% of patients, respectively. Hormone therapy was administered to 13.4% of the patients (80% tamoxifen). Median tumour size was 14.5 mm (6, 11 and 35 mm for CS, CS+RT and mastectomy, respectively, P<0.0001). Nuclear grade was high in 21% of patients, intermediate in 38.5% and low in 40.5%. Excision was considered complete in 92% (CS) and 88.3% (CS+RT) of patients. Oestrogen receptors were positive in 69.8% of assessed cases (31%). Treatment modalities varied widely according to region: mastectomy rate, 20-37%; adjuvant RT, 84-96%; hormone treatment, 6-34%. Our survey on current DCIS management in France has highlighted correlations between pathological features (tumour size, margin and grade) and treatment options, with several similar variations to those observed in recent UK and US studies.
authors.affiliation: Radiation Oncology Department, Polyclinique Courlancy, Reims, France. bcutuli@oncorad.courlancy.fr
authors.forename: B
authors.initials: B
authors.lastname: Cutuli
authors.forename: C
authors.initials: C
authors.lastname: Lemanski
authors.forename: A
authors.initials: A
authors.lastname: Fourquet
authors.forename: B
authors.initials: B
authors.lastname: de Lafontan
authors.forename: S
authors.initials: S
authors.lastname: Giard
authors.forename: A
authors.initials: A
authors.lastname: Meunier
authors.forename: R
authors.initials: R
authors.lastname: Pioud-Martigny
authors.forename: F
authors.initials: F
authors.lastname: Campana
authors.forename: H
authors.initials: H
authors.lastname: Marsiglia
authors.forename: S
authors.initials: S
authors.lastname: Lancrenon
authors.forename: E
authors.initials: E
authors.lastname: Mery
authors.forename: F
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: E
authors.initials: E
authors.lastname: Fondrinier
authors.forename: C
authors.initials: C
authors.lastname: Tunon de Lara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008327:Mammography; D015412:Mastectomy, Segmental; D008875:Middle Aged; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant